Corline Biomedical AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-14.71	-23.19	-1.81	2.33	-6.92	Upgrade
Depreciation & Amortization	0.1	0.1	0.1	0.06	0.03	Upgrade
Asset Writedown & Restructuring Costs	-	9.99	-	-	-	Upgrade
Change in Accounts Receivable	-0.05	3.41	3	-6.6	-1.13	Upgrade
Change in Accounts Payable	-2.16	1.12	-2.37	2.38	0.52	Upgrade
Change in Other Net Operating Assets	-0.87	-0.06	1.97	-4.62	2.67	Upgrade
Operating Cash Flow	-17.69	-8.64	0.89	-6.45	-4.84	Upgrade
Capital Expenditures	-0.05	-	-0.13	-0.15	-0.14	Upgrade
Sale (Purchase) of Intangibles	-0.94	-7.5	-10.49	-8.85	-9.48	Upgrade
Investment in Securities	0	-	-	-	0.06	Upgrade
Investing Cash Flow	-0.98	-7.5	-10.62	-9	-9.56	Upgrade
Issuance of Common Stock	23.02	18	-	-	50.63	Upgrade
Other Financing Activities	-1.46	-1.21	0.54	0.03	-3.51	Upgrade
Financing Cash Flow	21.56	16.79	0.54	0.03	47.13	Upgrade
Net Cash Flow	2.89	0.66	-9.2	-15.43	32.73	Upgrade
Free Cash Flow	-17.74	-8.64	0.75	-6.61	-4.98	Upgrade
Free Cash Flow Margin	-206.57%	-50.02%	2.12%	-20.27%	-28.93%	Upgrade
Free Cash Flow Per Share	-0.72	-0.40	0.04	-0.30	-0.24	Upgrade
Cash Interest Paid	0	0.03	0.03	-	0.01	Upgrade
Levered Free Cash Flow	-13.2	-11.45	-9.32	-16.32	-12.17	Upgrade
Unlevered Free Cash Flow	-13.2	-11.43	-9.3	-16.32	-12.16	Upgrade
Change in Working Capital	-3.08	4.47	2.6	-8.84	2.06	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.